The ISPOR Nominations Committee has selected the following candidates as nominees for the ISPOR Board for consideration by the membership.
There are two candidates for each open position. Directors serve a three-year term from 2024 – 2027. The President-elect retains a seat on the Board for three years, first as President-elect for one year, then as President for one year, and finally as Immediate Past President for one year. All terms commence on July 1, 2024.
President-Elect
Carole Longson, PhD, MBE
Senior Independent Adviser
Life Science Policy, HTA and Market Access
Stockport, England, UK
Uwe Siebert, MD, MPH, ScD
Professor for Public Health, Medical Decision Making and Health Technology Assessment
UMIT TIROL - University for Health Sciences and Technology
Tirol, Austria
Director 1
Jagpreet Chhatwal, PhD, MS
Director, Institute for Technology Assessment
Massachusetts General Hospital Harvard Medical School and Massachusetts General Hospital
Boston, MA, USA
Daniel Ollendorf, PhD
Chief Scientific Officer and Director of HTA Methods and Engagement
Institute for Clinical and Economic Review
Boston, MA, USA
Director 2
Katja Rudell, PhD, MSc
Senior Director
Parexel International
London, England, UK
Director 3
Ramiro Gilardino, MD, MHS
Global HTA & Access Policy Lead at Global Access
MSD International
Zurich, Switzerland
Joshua Ray, MBA, MSc
Chapter Lead - Access Evidence
F. Hoffmann-La Roche Ltd
Basel, Switzerland
Director 4
Elisabeth Fenwick, PhD, MSc
Chief Science Officer
Open Health Group
London, England, UK
Hemant Phatak, PhD
Head, Global Health Economics and Outcomes Research
Amylyx
Needham, MA, USA
Thank you in advance for casting your vote before April 1, 2024. As a member you must log-in to your profile to access the ballot.
Forgot your password? Click here
Please contact membership@ispor.org for login issues.
Please contact governance@ispor.org with questions related to the elections.
ISPOR’s Campaigning Policy for candidates and members is at ISPOR Campaigning Policies 2022 (PDF).